{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:06:21Z","timestamp":1761948381780,"version":"3.40.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jmoldx.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T14:40:31Z","timestamp":1529592031000},"page":"600-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Validation and Implementation of BRCA1\/2 Variant Screening in Ovarian Tumor Tissue"],"prefix":"10.1016","volume":"20","author":[{"given":"Marthe M.","family":"de Jonge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-6295","authenticated-orcid":false,"given":"Ronald","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nienke","family":"van der Stoep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-1870","authenticated-orcid":false,"given":"Maartje","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juul T.","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalja T.","family":"ter Haar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Baalbergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique E.M.M.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein J.","family":"Kagie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike P.G.","family":"Vreeswijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja N.","family":"Gaarenstroom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent T.H.B.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjalling","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-7730","authenticated-orcid":false,"given":"Tom","family":"van Wezel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christi J.","family":"van Asperen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2018.05.005_bib1","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib5","first-page":"2433","article-title":"Frequency of germline and somatic BRCA1 mutations in ovarian cancer","volume":"4","author":"Berchuck","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib6","first-page":"5329","article-title":"BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study","volume":"60","author":"Baldwin","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1126\/science.aab4082","article-title":"Somatic mutation in cancer and normal cells","volume":"349","author":"Martincorena","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2016.10.006","article-title":"Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients","volume":"69","author":"Vergote","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib15","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1158\/1078-0432.CCR-14-0571","article-title":"Functional ex\u00a0vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment","volume":"20","author":"Naipal","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40265-016-0688-7","article-title":"PARP inhibitors in reproductive system cancers: current use and developments","volume":"77","author":"O'Sullivan Coyne","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib20","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib21","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib22","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib24","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/ejhg.2016.94","article-title":"New challenges for BRCA testing: a view from the diagnostic laboratory","volume":"24","author":"Wallace","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00428-016-1919-8","article-title":"NGS-based BRCA1\/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial","volume":"468","author":"Endris","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1373\/clinchem.2014.223040","article-title":"Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization","volume":"61","author":"Do","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib27","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/gim.2015.212","article-title":"Improving performance of multigene panels for genomic analysis of cancer predisposition","volume":"18","author":"Shirts","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/humu.21438","article-title":"LOVD v.2.0: the next generation in gene variant databases","volume":"32","author":"Fokkema","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib29","doi-asserted-by":"crossref","first-page":"34858","DOI":"10.18632\/oncotarget.16799","article-title":"Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing","volume":"8","author":"Shin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nbt.2198","article-title":"Performance comparison of benchtop high-throughput sequencing platforms","volume":"30","author":"Loman","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jmoldx.2014.11.004","article-title":"Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and\/or ovarian cancer","volume":"17","author":"Trujillano","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/humu.23137","article-title":"Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas","volume":"38","author":"Weren","year":"2017","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12907-015-0004-6","article-title":"A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing","volume":"15","author":"Ellison","year":"2015","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.18632\/oncotarget.6834","article-title":"BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing","volume":"7","author":"Mafficini","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.yexmp.2012.06.004","article-title":"Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis","volume":"94","author":"van Eijk","year":"2013","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsd\u00f3ttir","year":"2013","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)65461-2","article-title":"A high frequency of sequence alterations is due to formalin fixation of archival specimens","volume":"155","author":"Williams","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/1097-0215(20000701)87:1<110::AID-IJC16>3.0.CO;2-6","article-title":"Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer","volume":"87","author":"Sutcliffe","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.gie.2006.02.002","article-title":"ASGE guideline: colorectal cancer screening and surveillance","volume":"63","author":"Davila","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib41","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1200\/JCO.2010.30.1010","article-title":"BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors","volume":"28","author":"Veeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jnci\/djq509","article-title":"Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2","volume":"103","author":"Drew","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib43","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib44","doi-asserted-by":"crossref","first-page":"vi93","DOI":"10.1093\/annonc\/mdm234","article-title":"Founder mutations in BRCA1 and BRCA2 genes","volume":"18","author":"Ferla","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/ng1197-341","article-title":"BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients","volume":"17","author":"Petrij-Bosch","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1590\/S1415-47572009005000049","article-title":"Genomic rearrangements in BRCA1 and BRCA2: a literature review","volume":"32","author":"Ewald","year":"2009","journal-title":"Gen Mol Biol"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib47","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1634\/theoncologist.2012-0452","article-title":"BRCA1\/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management","volume":"18","author":"Lindor","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/humu.23375","article-title":"An evaluation of the challenges to developing tumour BRCA1 and BRCA2 testing methodologies for clinical practice","volume":"39","author":"Ellison","year":"2018","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/j.gastro.2015.07.036","article-title":"American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome","volume":"149","author":"Rubenstein","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40246-017-0110-x","article-title":"Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology","volume":"11","author":"Buzolin","year":"2017","journal-title":"Hum Genomics"},{"key":"10.1016\/j.jmoldx.2018.05.005_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: ten years of next-generation sequencing technologies","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat Rev Genet"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157818300989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157818300989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T11:15:08Z","timestamp":1560856508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157818300989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1525157818300989"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2018.05.005","relation":{},"ISSN":["1525-1578"],"issn-type":[{"type":"print","value":"1525-1578"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation and Implementation of BRCA1\/2 Variant Screening in Ovarian Tumor Tissue","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}